United States Influenza Vaccines Market Report 2025: Industry Size, Market Shares Data, Latest Trends, Insights, Growth Potential, CAGR Forecasts 2019-2023 & 2024-2033
29. Oktober 2024 10:59 ET
|
Research and Markets
Dublin, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The "United States Influenza Vaccines Market Report 2025: Industry Size, Market Shares Data, Latest Trends, Insights, Growth Potential, CAGR Forecasts to...
mRNA Vaccine and Therapeutics Market Global Report to 2035, with Profiles of Arcturus Therapeutics, BioNTech, CureVac, Ethris, Immorna, Moderna, Providence Therapeutics and Suzhou Abogen Biosciences
26. September 2024 07:21 ET
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "mRNA Vaccine and Therapeutics Market Industry Trends and Global Forecasts to 2035: Distribution by Application Area, Target Disease Indication and...
Adult Vaccine Market Forecasts Report and Competitive Landscape 2024-2032 Featuring GlaxoSmithKline, AstraZeneca, Sanofi Pasteur, Pfizer, and CSL
10. September 2024 07:12 ET
|
Research and Markets
Dublin, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The "Adult Vaccine Market Report, Forecast by Disease, Countries and Company Analysis, 2024-2032" report has been added to ResearchAndMarkets.com's...
COVID-19 Vaccines Business Research Report 2024: Doses to Reach a Projected 4.2 Billion by 2025 - Global Market Forecast to 2030
28. August 2024 04:45 ET
|
Research and Markets
Dublin, Aug. 28, 2024 (GLOBE NEWSWIRE) -- The "COVID-19 Vaccines - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for COVID-19...
Pfizer und BioNTech geben Update zu mRNA-basiertem Kombinationsimpfstoffprogramm gegen Grippe und COVID-19 bei Personen im Alter von 18 bis 64 Jahren bekannt
16. August 2024 06:45 ET
|
BioNTech SE
Pfizers und BioNTechs Kombinationsimpfstoffkandidat gegen Grippe und COVID-19 hat in einer Phase-3-Studie eines ihrer beiden primären Ziele zur Immunogenität erreichtDie Studie erreichte eines ihrer...
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
16. August 2024 06:45 ET
|
BioNTech SE
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectivesThe trial did not meet one of its primary...
BioNTech gibt erste positive Ergebnisse aus laufender Phase-2-Studie mit mRNA-basiertem Immuntherapiekandidaten BNT111 bei fortgeschrittenem Hautkrebs bekannt
30. Juli 2024 06:45 ET
|
BioNTech SE
Primärer Endpunkt in Phase-2-Studie erreicht, in der der mRNA-Immuntherapiekandidat BNT111 in Kombination mit dem PD-1-Checkpoint-Inhibitor Cemiplimab evaluiert wirdDaten zeigten eine statistisch...
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
30. Juli 2024 06:45 ET
|
BioNTech SE
Primary endpoint met in a Phase 2 trial evaluating the investigational mRNA immunotherapy BNT111 in combination with the PD-1 checkpoint inhibitor cemiplimabData demonstrated a statistically...
mRNA Platform Global Strategic Research Analysis 2023-2030: US Holds Leading Position, while Asia-Pacific Exhibits Lucrative Growth in mRNA Vaccines Market
09. Juli 2024 06:09 ET
|
Research and Markets
Dublin, July 09, 2024 (GLOBE NEWSWIRE) -- The "mRNA Platform - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for mRNA Platform was...
Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an Omikron JN.1 angepassten COVID-19-Impfstoff in der Europäischen Union
27. Juni 2024 10:30 ET
|
BioNTech SE
Der aktualisierte COVID-19-Impfstoff ist auf die Omikron JN.1-Sublinie von SARS-CoV-2 zugeschnitten und wird für Personen ab 6 Monaten empfohlenDie Beurteilung basiert auf präklinischen und...